Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Farmers Insurance
QuintilesIMS
Healthtrust
Chinese Patent Office
Moodys
Accenture
Argus Health
Queensland Health

Generated: May 24, 2018

DrugPatentWatch Database Preview

ASENDIN Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Asendin patents expire, and what generic alternatives are available?

Asendin is a drug marketed by Lederle and is included in one NDA.

The generic ingredient in ASENDIN is amoxapine. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the amoxapine profile page.
Summary for ASENDIN
Drug patent expirations by year for ASENDIN
Synonyms for ASENDIN
(E)-2-chloro-11-(piperazin-1-yl)dibenzo[b,f][1,4]oxazepine
028A445
13-chloro-10-(piperazin-1-yl)-2-oxa-9-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3,5,7,9,12,14-heptaene
13-chloro-10-(piperazin-1-yl)-2-oxa-9-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,9,12,14-heptaene
13-chloro-10-(piperazin-1-yl)-2-oxa-9-azatricyclo[9.4.0.0;{3,8}]pentadeca-1(11),3(8),4,6,9,12,14-heptaene
13-CHLORO-10-(PIPERAZIN-1-YL)-2-OXA-9-AZATRICYCLO[9.4.0.0(3),?]PENTADECA-1(11),3(8),4,6,9,12,14-HEPTAENE
14028-44-5
2-Chlor-11-(1-piperazinyl)dibenz(b,f)(1,4)oxazepin
2-Chloro-11-(1-piperazinyl)- dibenz[b,f][1,4]oxazepine
2-Chloro-11-(1-piperazinyl)-dibenz[b,f][1,4]oxazepine
2-Chloro-11-(1-piperazinyl)dibenz(b,f)(1,4)oxazepine
2-Chloro-11-(1-piperazinyl)dibenz[b,f]-1,4-oxazepine
2-Chloro-11-(1-piperazinyl)dibenz[b,f][1,4]oxazepine
2-Chloro-11-(1-piperazinyl)dibenzo[b,f]-1,4-oxazepine
2-Chloro-11-(1-piperazinyl)dibenzo[b,f][1,4]oxazepine
2-Chloro-11-(1-piperazinyl)dibenzo[b,f][1,4]oxazepine #
2-chloro-11-(piperazin-1-yl)dibenzo[b,f][1,4]oxazepine
2-chloro-11-piperazin-1-yldibenzo[b,f][1,4]oxazepine
8-chloranyl-6-piperazin-1-yl-benzo[b][1,4]benzoxazepine
8-chloro-6-(1-piperazinyl)benzo[b][1,4]benzoxazepine
8-chloro-6-piperazin-1-yl-benzo[b][1,4]benzoxazepine
8-chloro-6-piperazin-1-ylbenzo[b][1,4]benzoxazepine
8-chloro-6-piperazin-1-ylbenzo[b][1,5]benzoxazepine
A-129
A807639
AB00052421_14
AB00052421_15
AB00052421-13
ABP000992
AC-5495
AC1L1D2U
AKOS015895092
Amoxan
Amoxapin
Amoxapina
Amoxapina [INN-Spanish]
amoxapine
Amoxapine (JP15/USP/INN)
Amoxapine (JP17/USP/INN)
Amoxapine [USAN:BAN:INN:JAN]
Amoxapine [USAN:USP:INN:BAN:JAN]
Amoxapine, 1.0 mg/mL in methanol, certified reference material
Amoxapine, Pharmaceutical Secondary Standard; Certified Reference Material
Amoxapine, United States Pharmacopeia (USP) Reference Standard
Amoxapinum
Amoxapinum [INN-Latin]
Amoxepine
amoxipine
AN-10914
Ascendin
Asendin (TN)
Asendis
Asendis (TN)
BC657161
BDBM22870
BG0035
BPBio1_000094
BRD-K02265150-001-05-9
BRN 0832057
BSPBio_000084
BSPBio_002654
C-54133
C17H16ClN3O
CAS-14028-44-5
CCG-39135
CHEBI:2675
CHEMBL1113
CL 67,772
CL 67772
CL-67,772
CL-67772
CPD000058416
CS-4485
CTK8F7751
D00228
D09IOI
DB00543
Defanyl
Defanyl (TN)
Demolox
Demolox (TN)
Desmethylloxapin
Desmethylloxapine
DIBENZ(b,f)(1,4)OXAZEPINE, 2-CHLORO-11-(1-PIPERAZINYL)-
Dibenz[b,f][1,4]oxazepine, 2-chloro-11-(1-piperazinyl)-
Dibenzo[b,f][1,4]oxazepine, 2-chloro-11-(1-piperazinyl)-
DivK1c_000236
DSSTox_CID_2598
DSSTox_GSID_22598
DSSTox_RID_76652
DTXSID7022598
EINECS 237-867-1
EU-0100116
FT-0659871
GTPL201
HE004626
HMS1568E06
HMS2089G10
HMS2093N08
HMS2095E06
HMS2231E13
HMS3259G08
HMS3260G14
HMS3370P03
HMS500L18
HY-B0991
I06-0520
IDI1_000236
J-007373
KBio1_000236
KBio2_000926
KBio2_003494
KBio2_006062
KBio3_001874
KBioGR_001656
KBioSS_000926
KS-000014ZS
KS-1197
L001293
Lopac-A-129
Lopac0_000116
LP00116
LS-61563
MCULE-9583761109
MFCD00069210
MLS000069371
MolPort-003-666-768
Moxadil
Moxadil (TN)
NC00546
NCGC00015004-01
NCGC00015004-02
NCGC00015004-03
NCGC00015004-04
NCGC00015004-05
NCGC00015004-06
NCGC00015004-07
NCGC00015004-08
NCGC00015004-09
NCGC00015004-10
NCGC00015004-11
NCGC00015004-13
NCGC00023887-03
NCGC00023887-04
NCGC00023887-05
NCGC00023887-06
NCGC00255124-01
NCGC00260801-01
NINDS_000236
NSC-759559
NSC759559
O286
Opera_ID_33
PDSP1_001609
PDSP2_001593
Pharmakon1600-02300161
PL045631
Prestwick_503
Prestwick0_000102
Prestwick1_000102
Prestwick2_000102
Prestwick3_000102
QWGDMFLQWFTERH-UHFFFAOYSA-N
R63VQ857OT
REGID_for_CID_2170
s4218
SAM002564189
SBI-0050104.P003
SC-79931
SCHEMBL33950
SMR000058416
SPBio_001150
SPBio_002023
Spectrum_000446
Spectrum2_001245
SPECTRUM2300161
Spectrum3_001067
Spectrum4_001218
Spectrum5_001284
SR-01000003001
SR-01000003001-2
Tox21_110064
Tox21_110064_1
Tox21_302352
Tox21_500116
UNII-R63VQ857OT
VA10272
Z1551429736
ZINC931

US Patents and Regulatory Information for ASENDIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lederle ASENDIN amoxapine TABLET;ORAL 018021-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Lederle ASENDIN amoxapine TABLET;ORAL 018021-004 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Lederle ASENDIN amoxapine TABLET;ORAL 018021-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Lederle ASENDIN amoxapine TABLET;ORAL 018021-003 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for ASENDIN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lederle ASENDIN amoxapine TABLET;ORAL 018021-003 Approved Prior to Jan 1, 1982 ➤ Sign Up ➤ Sign Up
Lederle ASENDIN amoxapine TABLET;ORAL 018021-001 Approved Prior to Jan 1, 1982 ➤ Sign Up ➤ Sign Up
Lederle ASENDIN amoxapine TABLET;ORAL 018021-001 Approved Prior to Jan 1, 1982 ➤ Sign Up ➤ Sign Up
Lederle ASENDIN amoxapine TABLET;ORAL 018021-002 Approved Prior to Jan 1, 1982 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Farmers Insurance
Cipla
Dow
Queensland Health
Chubb
Johnson and Johnson
Argus Health
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.